Natural history of patients presenting biochemical recurrence after radical prostatectomy: Some good news?

European Urology

Volumn 59, Issue 6, 2011, Pages 900-901

  Guillonneau, Bertrand D ^a   Fizazi, Karim ^b  

^a GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BIOCHEMICAL RECURRENCE; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; DEATH; DISEASE SURVEILLANCE; EDITORIAL; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MALE; MEDICAL HISTORY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RECURRENT CANCER; SALVAGE THERAPY;

AGE FACTORS; DISEASE-FREE SURVIVAL; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79955604902     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.02.043     Document Type: Editorial

References (4)

1. S.A. Boorjian, R.H. Thompson, and M.K. Tollefson Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence Eur Urol. 57 2011 893 899
2. S.J. Freedland, E.B. Humphreys, and L.A. Mangold Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 2005 433 439 (Pubitemid 41124175)
3. F.H. Schröder, J. Hugosson, and M.J. Roobol ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
4. G.L. Andriole, E.D. Crawford, and R.L. Grubb III PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310 1319